Greenstone Biosciences
$10.0M
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
Greenstone Biosciences is currently valued at $123.0M as of May 8, 2025. The company has raised a total of $20.2M in funding.
Capital Efficiency
With a capital efficiency ratio of 6.09x, Greenstone Biosciences has achieved a valuation that is 6.09 times the total capital raised. This metric indicates strong capital efficiency and effective deployment of investor funds.
Investment Perspective
Greenstone Biosciences's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is Greenstone Biosciences Worth in 2025?
As of 2025, Greenstone Biosciences is valued at $123.0M, based on the company's Early Stage VC funding round in May 8, 2025. This valuation positions Greenstone Biosciences as one of the leading private companies in the sector.
Greenstone Biosciences Valuation History
Greenstone Biosciences's funding history demonstrates steady growth and investor confidence.
How Greenstone Biosciences Valuation is Determined
Private company valuations like Greenstone Biosciences's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
Greenstone Biosciences Valuation FAQs
Is Greenstone Biosciences profitable?
Greenstone Biosciences has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does Greenstone Biosciences's valuation compare to competitors?
Greenstone Biosciences is valued at $123.0M, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will Greenstone Biosciences IPO?
Greenstone Biosciences has not announced plans for an initial public offering. Until an IPO, investors can access Greenstone Biosciences shares through secondary market platforms.